Skip to content

Home Search Authors Pakistan News Saved

SciRah

SciRah does not host or store research papers. Results come live from free, official scholarly APIs, and every paper links back to its original source.

Data sources

OpenAlex
Semantic Scholar
Crossref
CORE
arXiv
PubMed

Privacy policy Terms of service

M. Stroh · SciRah

Researcher profile · Semantic Scholar

M. Stroh

Share profile

M. Stroh — researcher profile on SciRah

h-index: 16
Works: 49
Citations: 1,050

Most-cited papers

Efficacy and safety of intranasal peptide YY3-36 for weight reduction in obese adults.
I. Gantz, N. Erondu, M. Mallick, B. Musser +10 more
2007Journal of Clinical Endocrinology and Metabolism169 citations
Semantic Scholar
Clinical Pharmacokinetics and Pharmacodynamics of Atezolizumab in Metastatic Urothelial Carcinoma
M. Stroh, H. Winter, M. Marchand, L. Claret +9 more
2017Clinical pharmacology and therapy146 citations
Semantic Scholar
Single‐Dose Administration of MK‐0657, an NR2B‐Selective NMDA Antagonist, Does Not Result in Clinically Meaningful Improvement in Motor Function in Patients With Moderate Parkinson's Disease
C. Addy, C. Assaid, D. Hreniuk, M. Stroh +12 more
2009Journal of clinical pharmacology66 citations
Semantic Scholar
A Model of Overall Survival Predicts Treatment Outcomes with Atezolizumab versus Chemotherapy in Non–Small Cell Lung Cancer Based on Early Tumor Kinetics
L. Claret, Jin Y. Jin, C. Ferté, H. Winter +10 more
2018Clinical Cancer Research64 citations Open access
Semantic Scholar
Phase I, First-in-Human Study of the Probody Therapeutic CX-2029 in Adults with Advanced Solid Tumor Malignancies
M. Johnson, A. El-Khoueiry, Navid Hafez, N. Lakhani +10 more
2021Clinical Cancer Research57 citations Open access
Semantic Scholar
RNA-Induced Silencing Complex-Bound Small Interfering RNA Is a Determinant of RNA Interference-Mediated Gene Silencing in Mice
Jie Wei, Jeff Jones, Jing Kang, A. Card +13 more
2011Molecular Pharmacology57 citations
Semantic Scholar
First-in-human trial of a poly(ADP)-ribose polymerase (PARP) inhibitor MK-4827 in advanced cancer patients with antitumor activity in BRCA-deficient tumors and sporadic ovarian cancers (soc).
W. Schelman, S. Sandhu, V. M. García, G. Wilding +9 more
2010Journal of Clinical Oncology53 citations
Semantic Scholar
A survey of new oncology drug approvals in the USA from 2010 to 2015: a focus on optimal dose and related postmarketing activities
D. Lu, T. Lu, M. Stroh, R. Graham +5 more
2016Cancer Chemotherapy and Pharmacology47 citations Open access
Semantic Scholar
CX-072 (pacmilimab), a Probody® PD-L1 inhibitor, in advanced or recurrent solid tumors (PROCLAIM-CX-072): an open-label dose-finding and first-in-human study
A. Naing, F. Thistlethwaite, E. D. de Vries, F. Eskens +14 more
2021Journal for ImmunoTherapy of Cancer43 citations Open access
Semantic Scholar
A PK/PD Analysis of Circulating Biomarkers and Their Relationship to Tumor Response in Atezolizumab‐Treated non‐small Cell Lung Cancer Patients
Ida Netterberg, Chi-Chung Li, L. Molinero, N. Budha +4 more
2018Clinical pharmacology and therapy40 citations Open access
Semantic Scholar
Randomized Phase II Trial of Parsatuzumab (Anti‐EGFL7) or Placebo in Combination with FOLFOX and Bevacizumab for First‐Line Metastatic Colorectal Cancer
R. García-Carbonero, E. Van Cutsem, F. Rivera, J. Jassem +16 more
2017The Oncologist30 citations Open access
Semantic Scholar
362 First in human trial of a poly(ADP)-ribose polymerase (PARP) inhibitor MK-4827 in advanced cancer patients (p) with antitumor activity in BRCA-deficient and sporadic ovarian cancers
R. Wenham, S. Sandhu, G. Wilding, Linda Z. Sun +6 more
201028 citations
Semantic Scholar
CX-072 (pacmilimab), a Probody PD-L1 inhibitor, in combination with ipilimumab in patients with advanced solid tumors (PROCLAIM-CX-072): a first-in-human, dose-finding study
R. Sanborn, O. Hamid, E. D. de Vries, P. Ott +9 more
2021Journal for ImmunoTherapy of Cancer27 citations Open access
Semantic Scholar
Translation of Anticancer Efficacy From Nonclinical Models to the Clinic
M. Stroh, Du-Da G. Dan, Chris H.M. Takimoto, Shinji Yamazaki +1 more
2014CPT: Pharmacometrics & Systems Pharmacology23 citations Open access
Semantic Scholar
Using human recombinant UDP-glucuronosyltransferase isoforms and a relative activity factor approach to model total body clearance of laropiprant (MK-0524) in humans
C. Gibson, P. Lu, C. Maciolek, Christen Wudarski +5 more
2013Xenobiotica; the fate of foreign compounds in biological systems22 citations
Semantic Scholar
Challenges and Opportunities for Quantitative Clinical Pharmacology in Cancer Immunotherapy: Something Old, Something New, Something Borrowed, and Something Blue
M. Stroh, D. Carlile, Chi-Chung Li, J. Wagg +9 more
2015CPT: Pharmacometrics & Systems Pharmacology17 citations Open access
Semantic Scholar
Quantitative Systems Pharmacology Model of a Masked, Tumor‐Activated Antibody
M. Stroh, J. Sagert, J. Burke, J. Apgar +3 more
2019CPT: Pharmacometrics & Systems Pharmacology16 citations Open access
Semantic Scholar
Model‐Informed Drug Development of the Masked Anti‑PD‑L1 Antibody CX‐072
M. Stroh, Michelle Green, B. Millard, J. Apgar +8 more
2020Clinical pharmacology and therapy14 citations
Semantic Scholar
Exposure–Response and Tumor Growth Inhibition Analyses of the Monovalent Anti-c-MET Antibody Onartuzumab (MetMAb) in the Second- and Third-Line Non-Small Cell Lung Cancer
Kelong Han, P. Chanu, F. Jonsson, H. Winter +3 more
2016AAPS Journal13 citations Open access
Semantic Scholar
CX-2009, a CD166-directed probody drug conjugate (PDC): Results from the first-in-human study in patients (Pts) with advanced cancer including breast cancer (BC).
V. Boni, H. Burris, Joyce F. Liu, A. Spira +16 more
202011 citations
Semantic Scholar
Evidence of intratumoral localization, activation, and immunomodulatory effect of CX-072, a probody therapeutic targeting PD-L1, in a phase I/II trial.
S. Lyman, A. Naing, Ivan A Zein, Bruce Howng +7 more
20209 citations
Semantic Scholar
Should Therapeutic Drug Monitoring for Monoclonal Antibodies Remain the Exception or Become the Norm?
M. Stroh, B. Lum
2016Clinical pharmacology and therapy9 citations
Semantic Scholar
Clinical Pharmacology and Translational Considerations in the Development of CRISPR‐Based Therapies
A. Abdelhady, Jonathan Phillips, Yuanxin Xu, M. Stroh
2023Clinical pharmacology and therapy8 citations Open access
Semantic Scholar
Randomized Phase II Trial of Parsatuzumab (Anti-EGFL7) or Placebo in Combination with FOLFOX and Bevacizumab for First-Line Metastatic Colorectal Cancer.
R. García-Carbonero, E. Van Cutsem, F. Rivera, J. Jassem +16 more
2017The Oncologist7 citations Open access
Semantic Scholar
Meta-analysis of published efficacy and safety data for docetaxel in second-line treatment of patients with advanced non-small-cell lung cancer
M. Stroh, Michelle Green, E. Cha, Nancy S Zhang +2 more
2016Cancer Chemotherapy and Pharmacology7 citations
Semantic Scholar
First-in-human study of AMG 900, an oral pan-Aurora kinase inhibitor, in adult patients (pts) with advanced solid tumors.
M. Carducci, M. Shaheen, C. Paller, J. Bauman +6 more
20127 citations
Semantic Scholar
The minimal impact of food on the pharmacokinetics of ridaforolimus
M. Stroh, Xiaodong Li, S. Marsilio, D. Panebianco +8 more
2012Cancer Chemotherapy and Pharmacology6 citations
Semantic Scholar
The effect of multiple doses of rifampin and ketoconazole on the single-dose pharmacokinetics of ridaforolimus
M. Stroh, J. Palcza, J. McCrea, S. Marsilio +10 more
2012Cancer Chemotherapy and Pharmacology6 citations
Semantic Scholar
Model-Based Decision Making in Early Clinical Development: Minimizing the Impact of a Blood Pressure Adverse Event
M. Stroh, C. Addy, Yunhui Wu, S. Stoch +10 more
2009AAPS Journal6 citations Open access
Semantic Scholar
Onartuzumab with or without bevacizumab in combination with weekly paclitaxel does not prolong QTc or adversely affect other ECG parameters in patients with locally recurrent or metastatic triple-negative breast cancer
M. Borin, Meng Chen, S. Mocci, I. Rubets +3 more
2015Cancer Chemotherapy and Pharmacology5 citations
Semantic Scholar
Lack of meaningful effect of ridaforolimus on the pharmacokinetics of midazolam in cancer patients: Model prediction and clinical confirmation
M. Stroh, J. Talaty, Punam Sandhu, J. McCrea +12 more
2014Journal of clinical pharmacology5 citations
Semantic Scholar
Influence of Laropiprant, a Selective Prostaglandin D2 Receptor 1 Antagonist, on the Pharmacokinetics and Pharmacodynamics of Warfarin
J. Schwartz, Fang Liu, M. Stroh, A. Gipson +4 more
2009American Journal of Therapeutics5 citations
Semantic Scholar
Simultaneous Pharmacokinetic Model for Rolofylline and both M1-trans and M1-cis Metabolites
M. Stroh, M. Hutmacher, Jian-Mei Pang, R. Lutz +2 more
2013AAPS Journal4 citations Open access
Semantic Scholar
Pharmacokinetics of Laropiprant and Glucuronide Metabolite in Patients with Severe Renal Insufficiency
M. Stroh, Larissa A. Wenning, W. Luo, Rajesh Desai +10 more
2009American Journal of Therapeutics4 citations
Semantic Scholar
Effects of laropiprant, a selective prostaglandin D(2) receptor 1 antagonist, on the pharmacokinetics of rosiglitazone.
J. Schwartz, M. Stroh, Bing Gao, Fang Liu +6 more
2009Cardiovascular Therapeutics4 citations Open access
Semantic Scholar
In vivo CRISPR/Cas9 editing of the TTR gene with NTLA-2001 in patients with transthyretin amyloidosis- dose selection considerations
E. Gane, J. Täubel, B. Pilebro, M. Fontana +17 more
2022Journal of Hepatology3 citations
Semantic Scholar
Preliminary results of the first-in-human, dose-finding PROCLAIM-CX-072 trial of the PD-L1 Probody therapeutic CX-072 as monotherapy in patients (pts) with advanced solid tumors.
K. Autio, H. Arkenau, B. O'Neil, J. Bendell +14 more
20183 citations
Semantic Scholar
The Effects of Multiple Doses of Rolofylline on the Single-Dose Pharmacokinetics of Midazolam in Healthy Subjects
M. Stroh, V. Dishy, W. Radziszewski, Eunhee Hwang +6 more
2010American Journal of Therapeutics3 citations
Semantic Scholar
Abstract 212: CD166-DM4 probody drug conjugate (CX-2009) treatment of 198 patient-derived xenograft models (PDX) in a mouse clinical trial format
Bob Y. Liu, Joel Shen, M. Will, Sreeni Yalamanchili +8 more
2019Experimental and Molecular Therapeutics2 citations
Semantic Scholar
Preliminary population pharmacokinetics supports phase II dose selection for masked anti-PD-L1 antibody CX-072.
M. Stroh, Michelle Green, B. Millard, W. Garner +3 more
2020Journal of Clinical Oncology1 citations
Semantic Scholar
Preliminary clinical pharmacokinetics and dose-response to support a phase II dose selection for CX-2009: A masked probody drug conjugate to CD166.
M. Stroh, Rachel W. Li, Hong Lu, R. Wada +3 more
20201 citations
Semantic Scholar
Designing In and Around Tolerability Considerations for Immunotherapy Combinations
M. Stroh
2018Clinical pharmacology and therapy1 citations
Semantic Scholar
A single supratherapeutic dose of ridaforolimus does not prolong the QTc interval in patients with advanced cancer
Richard M. Lush, A. Patnaik, Daniel M. Sullivan, K. Papadopoulos +12 more
2012Cancer Chemotherapy and Pharmacology1 citations Open access
Semantic Scholar
First in human trial of the poly(ADP)-ribose polymerase inhibitor MK-4827 in patients with advanced cancer with antitumor activity in BRCA-deficient and sporadic ovarian cancers
R. Wenham, G. Wilding, R. Baird, Linda Z. Sun +6 more
20111 citations
Semantic Scholar
A Single Supratherapeutic Dose of Rolofylline Does Not Prolong the QTcF Interval in Healthy Volunteers
W. Radziszewski, E. Lai, Nicole Lazarus Shipitofsky, M. Stroh +6 more
2010American Journal of Therapeutics1 citations
Semantic Scholar
Preliminary single-dose clinical pharmacokinetics of an anti–PD-L1 Probody therapeutic (Pb-Tx) in cancer patients.
M. Stroh, L. Serwer, Hong Lu, Vanessa Huels +8 more
20180 citations
Semantic Scholar
A PKPD analysis of circulating biomarkers and their relationship to the tumor size time-course in atezolizumab treated non-small cell lung cancer patients
Ida Netterberg, Chunze Li, L. Molinero, N. Budha +4 more
20170 citations
Semantic Scholar
To assess the effect of ridaforolimus on the QTc interval in patients with advanced cancer.
Daniel C. Sullivan, A. Patnaik, K. Papadopoulos, J. McCrea +10 more
2011Journal of Clinical Oncology0 citations
Semantic Scholar
The effect of hepatic insufficiency on the pharmacokinetics of ridaforolimus.
J. McCrea, M. Stroh, X.-N. Li, V. Schulz +7 more
2011Journal of Clinical Oncology0 citations
Semantic Scholar

Frequent co-authors

Invite them to SciRah by sharing their profile.

J. Wagner×11
Invite
J. Wagner — researcher profile on SciRah
E. Lai×6
Invite
E. Lai — researcher profile on SciRah
V. Boni×5
Invite
V. Boni — researcher profile on SciRah
J. Richardson×5
Invite
J. Richardson — researcher profile on SciRah

A. Johnson-Levonas

×5

Invite

A. Johnson-Levonas — researcher profile on SciRah

Invite

K. Orford — researcher profile on SciRah

Invite

J. McCrea — researcher profile on SciRah

Invite

Jin Y. Jin — researcher profile on SciRah

J. García-Corbacho×4

Invite

J. García-Corbacho — researcher profile on SciRah

Invite

A. Hannah — researcher profile on SciRah

Invite

A. Spira — researcher profile on SciRah

Invite

B. Millard — researcher profile on SciRah